Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People whose ability to carry out daily activities is largely unaffected by their illness (confirm with trial site for exact scoring)
• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), either through imaging or tissue testing
• People whose liver cancer cannot be surgically removed and has either stayed mainly in the liver or spread to a small number of sites (no more than 5 areas of spread across no more than 3 organs, not including the brain)
• People who have at least one tumour that can be measured using standard imaging methods
• People whose tumours can all be targeted within a radiation treatment area
• People with a certain level of liver function, assessed as Child-Pugh A or B with a score of 7 (confirm with trial site)
• People who have previously received other systemic (whole-body) treatments, as long as those treatments did not include the combination of tislelizumab and regorafenib
• People with adequate blood count and kidney function (confirm with trial site for specific thresholds)
• People with a life expectancy of at least 3 months
• People who are willing to take part and sign a written consent form

Who may not be able to join:

• People who have previously had a liver transplant
• People with serious complications from severe liver scarring, including a history of bleeding from veins in the food pipe or stomach, episodes of brain confusion caused by liver failure, or large amounts of fluid build-up in the abdomen
• People with active autoimmune diseases, or a history of autoimmune disease (conditions where the immune system attacks the body's own tissues)
• People living with HIV or AIDS
• People who have a known allergy to any ingredient in tislelizumab or regorafenib
• People who have already had radiotherapy to the same areas that would need to be treated in this trial
• People whose tumours are located in positions where safe radiation doses cannot be delivered without exceeding safe limits for nearby healthy organs
• People who cannot tolerate radiation or systemic treatment due to heart problems or uncontrolled high blood pressure
• People with a history of other cancers, except for certain skin cancers or early-stage cervical changes that have been fully treated and cured

Important: Always verify eligibility with the trial site directly before applying.